Galectin Therapeutics, based in Norcross, Georgia, focuses on developing therapies for fibrotic diseases, severe skin diseases, and cancer, with its lead drug, belapectin, targeting galectin-3. The company, with 14 employees, has programs for metabolic dysfunction-associated steatohepatitis and advanced cancers.
Galectin Therapeutics (GALT) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Galectin Therapeutics's actual EPS was -$0.19, missing the estimate of -$0.16 per share, resulting in a -16.42% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
